Dulaglutide (LY-2189265) for the treatment of type 2 diabetes

References

• Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:911–922.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl 1):S14–80.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–336.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins for 2014. Exp Opin Pharmacother. 2015;16:43–62.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742.
   PubMed Web of Science ®Google Scholar
• Purnell TS, Joy S, Little E, et al. Patient preferences for noninsulin diabetes medications: a systematic review. Diabetes Care. 2014;37:2055–2062.
   PubMed Web of Science ®Google Scholar
• Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38:1161–1172.
   PubMed Web of Science ®Google Scholar
• Potts JE, Gray LJ, Brady EM, et al. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One. 2015;10:e0126769.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Hessler D, et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13:144–149.
   PubMed Web of Science ®Google Scholar
• Sanford M. Dulaglutide: first global approval. Drugs. 2014;74:2097–2103.
   PubMed Web of Science ®Google Scholar
• Kuritzky L, Umpierrez G, Ekoe JM, et al. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med. 2014;126:60–72.
   PubMed Web of Science ®Google Scholar
• Thompson AM, Trujillo JM. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015;49:351–359.
   PubMed Web of Science ®Google Scholar
• Edwards KL, Minze MG. Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes. Core Evidence. 2015;10:11–21.
   PubMed Web of Science ®Google Scholar
• Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287–296.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report: Trulicity (dulaglutide); 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002825/WC500179473.pdf
   Google Scholar
• Barrington P, Chien JY, Tibaldi F, et al. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab. 2011;13:434–438.
   PubMed Web of Science ®Google Scholar
• Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:426–433.
   PubMed Web of Science ®Google Scholar
• de la Pena A, Loghin C, Cui X, et al. Pharmacokinetics of once weekly dulaglutide in patients with type 2 diabetes mellitus. Diabetes. 2014;63:A251: 981-P.
   Web of Science ®Google Scholar
• European Medicines Agency. Trulicity: summary of product characteristics; 2015 Available from: http://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002825/WC500179470pdf
   Google Scholar
• Grunberger G, Chang A, Garcia Soria G, et al. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29:1260–1267.
   PubMed Web of Science ®Google Scholar
• Terauchi Y, Satoi Y, Takeuchi M, et al. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocr J. 2014;61:949–959.
   PubMed Web of Science ®Google Scholar
• Umpierrez G, Tofe Povedano S, Perez Manghi F, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168–2176.
   PubMed Web of Science ®Google Scholar
• Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37:2149–2158.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Blevins T, Rosenstock J, et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13:418–425.
   PubMed Web of Science ®Google Scholar
• Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349–1357.
   PubMed Web of Science ®Google Scholar
• Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38:2241–2249.
   PubMed Web of Science ®Google Scholar
• Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159–2167.
   PubMed Web of Science ®Google Scholar
• Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385:2057–2066.
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y, Fukushima M, et al. β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15:602.
   PubMed Web of Science ®Google Scholar
• Kim YG, Hahn S, Oh TJ, et al. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:900–909.
   PubMed Web of Science ®Google Scholar
• Miyagawa J, Odawara M, Takamura T, et al. Once weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomised phase 3 study. Diabetes Obes Metab. 2015;17:974–983.
   PubMed Web of Science ®Google Scholar
• Araki E, Inagaki N, Tanizawa Y, et al. Efficacy and safety of once weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once daily insulin glargine in Japanese patients with type 2 diabetes: a randomised, open-label, phase 3, non-inferiority study. Diabetes Obes Metab. 2015;17:994–1002.
   Web of Science ®Google Scholar
• Takamura T, Miyagawa J, Odawara M, et al. Efficacy and safety of once-weekly dulaglutide versus once-daily liraglutide in Japanese patients with type 2 diabetes. Diabetes. 2015;64(Suppl 1):A285: 1111-P.
   Google Scholar
• Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117–124.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289–297.
   PubMed Web of Science ®Google Scholar
• Weinstock RS, Guerci B, Umpierrez G, et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17:849–858.
   PubMed Web of Science ®Google Scholar
• Skrivanek Z, Gaydos BL, Chien JY, et al. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes Metab. 2014;16:748–756.
   PubMed Web of Science ®Google Scholar
• Syed YY, McCormack PL. Exenatide extended-release: an updated review of its use in type 2 diabetes mellitus. Drugs. 2015;75:1141–1152.
   PubMed Web of Science ®Google Scholar
• Tuttle KR, McKinney TD, Davidson JA, et al. The effects of once-weekly dulaglutide on kidney function in clinical trials. Diabetes. 2015;64(Suppl 1): A286:1114-P.
   Google Scholar
• Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64:731–737.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Sager PT, Atisso CM, et al. Once-weekly dulaglutide does not increase the risk for CV events in type 2 diabetes: a prespecified CV meta-analysis of prospectively adjudicated CV events. Diabetes. 2015;64(Suppl 1):A289: 1127-P.
   Google Scholar
• Matfin G, Van Brunt K, Zimmermann AG, et al. Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naive patients with type 2 diabetes. J Diabetes Sci Technol. 2015;9:1071–1079.
   PubMedGoogle Scholar
• Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6:19–28.
   PubMed Web of Science ®Google Scholar
• Yabe D, Kuwata H, Usui R, et al. Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points. Curr Med Res Opin. 2015;31:1267–1270.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Which incretin-based therapy for type 2 diabetes? Lancet. 2014;384:1325–1327.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015;54:1–21.
   PubMed Web of Science ®Google Scholar
• National Institute for health and Care Excellence. Type 2 diabetes: the management of type 2 diabetes: NICE Clinical Guideline 87; 2009 [cited 2015 July 23]. Available from: https://www.nice.org.uk/guidance/cg87
   Google Scholar
• Agence Nationale des Médicaments et des Produits de Santé. Stratégie médicamenteuse du contrôle glycémique du diabète de type 2: recommandations; 2013 [cited 2015 July 23]. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-02/10irp04_reco_diabete_type_2.pdf
   Google Scholar
• Jones AG, McDonald TJ, Shields BM, et al. Markers of beta-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care. 2015 Aug 4. pii: dc 150258. [Epub ahead of print].
   Web of Science ®Google Scholar
• Kozawa J, Inoue K, Iwamoto R, et al. Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. J Diabetes Investig. 2012;3:294–297.
   PubMed Web of Science ®Google Scholar
• Usui R, Yabe D, Kuwata H, et al. Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: association of remaining beta-cell function and achievement of HbA1c target one year after initiation. J Diabetes Complications. 2015;29:1203–1210.
   PubMed Web of Science ®Google Scholar
• Grunberger G, Forst T, Fernandez Lando L, et al. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide. Diabet Med. 2015 Jul 14. DOI:10.1111/dme.12833. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Reaney M, Yu M, Lakshmanan M, et al. Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab. 2015;17:896–903.
   PubMed Web of Science ®Google Scholar
• Henry RR, Rosenstock J, Logan D, et al. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications. 2014;28:393–398.
   PubMed Web of Science ®Google Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs–FDA and EMA assessment. N Engl J Med. 2014;370:794–797.
   PubMed Web of Science ®Google Scholar
• Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383:2008–2017.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists. Lancet Diabetes Endocrinol. 2015;3:667–669.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Charbonnel B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab. 2014;40:176–185.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36:2288–2296.
   PubMed Web of Science ®Google Scholar
• The U.S. National Institutes of Health. Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND); 2015 [cited 2015 July 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT01394952
   Google Scholar
• Scheen AJ. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Ann Endocrinol (Paris). 2013;74:515–522.
   PubMed Web of Science ®Google Scholar
• Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014;34:1174–1186.
   PubMed Web of Science ®Google Scholar
• Carris NW, Taylor JR, Gums JG. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. 2014;74:2141–2152.
   PubMed Web of Science ®Google Scholar
• Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228–2234.
   PubMed Web of Science ®Google Scholar
• Dejgaard TF, Knop FK, Tarnow L, et al. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes–a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study. BMJ Open. 2015;5:e007791.
   Web of Science ®Google Scholar
• Scott LJ. Liraglutide: a review of its use in the management of obesity. Drugs. 2015;75:899–910.
   PubMed Web of Science ®Google Scholar